FFA
AVIR icon

Farther Finance Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Farther Finance Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.57K Buy
494
+249
+102% +$1.27K ﹤0.01% 5310
2026
Q2 		$1.13K Buy
245
+85
+53% +$423 ﹤0.01% 5340
2026
Q1 		$904 Buy
160
+11
+7% +$51 ﹤0.01% 5137
2025
Q4 		$532 Hold
149
– – ﹤0.01% 5041
2025
Q3 		$432 Hold
149
– – ﹤0.01% 4576
2025
Q2 		$536 Buy
149
+3
+2% +$9 ﹤0.01% 4027
2025
Q1 		$416 Sell
146
-70
-32% -$218 ﹤0.01% 3806
2024
Q4 		$724 Hold
216
– – ﹤0.01% 3349
2024
Q3 		$724 Sell
216
-17
-7% -$62 ﹤0.01% 3333
2024
Q2 		$785 Sell
233
-68
-23% -$254 ﹤0.01% 3151
2024
Q1 		$1.2K Buy
301
+85
+39% +$333 ﹤0.01% 2699
2023
Q4 		$659 Buy
216
+78
+57% +$236 ﹤0.01% 2881
2023
Q3 		$414 Hold
138
– – ﹤0.01% 2317
2023
Q2 		$516 Hold
138
– – ﹤0.01% 2145
2023
Q1 		$462 Sell
138
-158
-53% -$641 ﹤0.01% 2023
2022
Q4 		$1.42K Buy
+296
New +$1.5K ﹤0.01% 1558

Other funds holding AVIR

VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's AVIR Position: Q3 2026 in Review

Farther Finance Advisors increased its Atea Pharmaceuticals (AVIR) stake by 102% in Q3 2026, buying an estimated $1.27K and bringing the position to 494 shares worth $2.57K. The position accounts for ﹤0.01% of the portfolio, ranked #5310.

Farther Finance Advisors first reported a position in AVIR in Q4 2022 and has held it in 16 quarters since. 3 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

  • Farther Finance Advisors held 494 shares of Atea Pharmaceuticals worth $2.57K as of Q3 2026.
  • Farther Finance Advisors bought 249 Atea Pharmaceuticals shares in Q3 2026, an estimated $1.27K.
  • Atea Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5310 holding.
  • Farther Finance Advisors first reported a position in Atea Pharmaceuticals in Q4 2022 and has held it in 16 quarters since.
  • 3 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.